Key Developments For Biocryst Pharmaceuticals, Inc.
Biocryst Pharmaceuticals, Inc. (BCRX.O) (Consolidated Issue listed on NASDAQ Global Market)
BioCryst Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of Common Stock
BioCryst Pharmaceuticals, Inc. announced pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million. All of the shares are being offered by BioCryst pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. BioCryst has also granted the underwriters a 30-day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over-allotments, if any. Morgan Stanley is acting as the sole book-runner for the offering, with JMP Securities and Oppenheimer & Co. acting as co-managers. The offering is expected to close on November 25, 2009.
BioCryst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. announced that it is offering to sell, to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. BioCryst also intends to grant the underwriters a 30 day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over allotments, if any. All of the shares in the offering are to be sold by BioCryst. Morgan Stanley will be acting as the sole book-runner for the offering, with JMP Securities and Oppenheimer & Co. acting as co-managers.
BioCryst Pharmaceuticals, Inc. Receives First Peramivir Order From U.S. Government
BioCryst Pharmaceuticals, Inc. announced that it has received an initial order for 10,000 courses of intravenous peramivir (600 mg once-daily for five days) with a value of $22.5 million under a newly issued contract with the Department of Health and Human Services .
BioCryst Pharmaceuticals, Inc.'s Partner Shionogi Files For Peramivir Regulatory Approval In Japan
BioCryst Pharmaceuticals, Inc. announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this filing, BioCryst will receive a regulatory payment of $7 million under its agreement with Shionogi.
BioCryst Pharmaceuticals, Inc. Announces Data From Phase 2 Study of Peramivir In Patients Hospitalized With Influenza Presented At XI International Symposium On Respiratory Viral Infections
BioCryst Pharmaceuticals, Inc. announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, during the XI International Symposium on Respiratory Viral Infections taking place in Bangkok, Thailand, February 19 through February 22, 2009. This exploratory Phase 2 trial compared the efficacy and safety of five days of therapy with either 200 mg intravenous (i.v.) peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice a day, in patients who required hospitalization related to influenza. The multicenter, randomized, double blind, double dummy, active controlled, Phase 2 study enrolled 137 patients, who tested positive by rapid antigen test (RAT) for influenza and had one or more criteria for hospitalization, namely: age greater than or equal to 60 years, chronic lung disease, congestive heart failure, diabetes mellitus, low oxygen saturation, low blood pressure, or severity of illness requiring supportive care. Of the 137 patients randomized, 122 age 19 to 101 years had influenza confirmed by polymerase chain reaction (PCR) testing and were included in the intent to treat infected (ITTI) patient population; 41 patients received oseltamivir 75 mg orally twice daily, 41 patients received 200 mg i.v. peramivir once daily and 40 patients received 400 mg i.v. peramivir once daily.
